diagnostics-impact on the premium channel - heidelberg engineering

Visionary Diagnostic Solutions

Kester Nahen, PhDManaging Director

SPECTRALIS Multimodal Imaging Platform

SPECTRALISWidefield OCT Module

SPECTRALIS Widefield OCT Module

55°30°

16,5 mm

SPECTRALIS Widefield OCT Module

Courtesy of Prof. Staurenghi, Milan

SPECTRALISMultiColor Module

MultiColor Imaging

View images of individual laser colors to gain better understanding of structural detail at different depths within the retina

Image courtesy of S. Wolf, MD, PhD, Bern, Switzerland

ERM, RNFL, macular pigment

blood vessels, blood, excudates

drusen, RPE, choroid

SPECTRALISWidefield Fundus Imaging Module

Widefield MultiColor Imaging

30°

55°

SPECTRALISOCT2 Module

Next generation OCT module

85 kHz A-scan rate

Scan time approx. cut in half

OCT2 scan speed improves workflow

OCT2 supports efficient workflow while performing dense volume scans Transverse Section Analysis (TSA)

Vitreoretinal interfaceRPEChoroid

OCT2 scan speed improves workflow

OCT-Angiography

OCT-Angiography - work in progress, not for sale

OCT2 scan speed improves workflow

OCT2 supports comprehensive scan protocols Glaucoma Module Premium Edition

Glaucoma Module Premium Edition is pending FDA approval

OCT2 image quality improves diagnostic potential

High image contrast vitreous to choroid

Reliable Multi-Layer Segmentation

OCT2

Foundation for Layer thickness analysis Transverse Section Analysis (TSA) OCT-Angiography

OCT-Angiography - work in progress, not for sale

GCL

OCT2 image quality improves diagnostic potential

Transverse Section Analysisof patient with drusen

OCT2 integrates with existing SPECTRALIS

OCT

OCT2

Analyses are fully compatible between both OCT generations

Ensures tracking progression over long periods of time using AutoRescan function and Active Eye Tracking

OCT2 integrates with existing SPECTRALIS

OCT

OCT2

SPEC

TRAL

IS

Analyses are fully compatible between both OCT generations

Ensures tracking progression over long periods of time using AutoRescan function and Active Eye Tracking

Makes the Spectralis a safe long term investment

SPECTRALISOCT-Angiography Module

OCT-Angiography is work in progress

Superficial Capillary Plexus

Depth-Selective Visualization of the Vascular Network

OCT-Angiography is work in progress

Superficial Capillary Plexus

Depth-Selective Visualization of the Vascular Network

OCT-Angiography is work in progress

Deep Capillary Plexus

Depth-Selective Visualization of the Vascular Network

OCT-Angiography is work in progress

Deep Capillary Plexus

Depth-Selective Visualization of the Vascular Network

OCT-Angiography is work in progress

Choriocapillaris

Depth-Selective Visualization of the Vascular Network

OCT-Angiography is work in progress

26

Sattler’s Layer

Depth-Selective Visualization of the Vascular Network

OCT-Angiography is work in progress

27

Haller’s Layer

Depth-Selective Visualization of the Vascular Network

OCT-Angiography is work in progress

CONFIDENTIAL 28

FA

BluePeak

ICGA

OCT Angio

OCT-Angiography is work in progress

SPECTRALISMultimodal

Imaging

CONFIDENTIAL 29

FA

BluePeak

ICGA

OCT Angio

SPECTRALISMultimodal

Imaging

OCT-Angiography is work in progress

CONFIDENTIAL 30

FA

BluePeak

ICGA

OCT Angio

OCT-Angiography is work in progress

SPECTRALISMultimodal

Imaging

CONFIDENTIAL 31

FA

BluePeak

ICGA

OCT Angio

SPECTRALISMultimodal

Imaging

OCT-Angiography is work in progress

CONFIDENTIAL 32

FA

BluePeak

ICGA

OCT Angio

OCT-Angiography is work in progress

SPECTRALISMultimodal

Imaging

CONFIDENTIAL 33

FA

BluePeak

ICGA

OCT Angio

SPECTRALISMultimodal

Imaging

OCT-Angiography is work in progress

CONFIDENTIAL 34

FA

BluePeak

ICGA

OCT Angio

OCT-Angiography is work in progress

SPECTRALISMultimodal

Imaging

SPECTRALIS – Expandable Imaging Platform

Explore New SPECTRALIS Modules Widefield OCT Widefield Fundus Imaging OCT2 OCT-Angiography

Enjoy Safe Investment SPECTRALIS systems purchased with Advanced

Upgrade Package or MultiColor module are upgradeable to OCT2

OCT-Angiography is work in progress

For 25 years Heidelberg Engineering has been providing solutions

to fundamental diagnostic challenges in ophthalmology.

With HRT and SPECTRALIS we have achieved this

for both glaucoma and retina.

The Cataract and Refractive Imaging Platform is currently under development and not for sale yet.

Now we intend to achieve the same for the current challenges in the field of

cataract and refractive surgery.

The Cataract and Refractive Imaging Platform is currently under development and not for sale yet.

Cataract Refractive Imaging Platform

Swept-Source OCT Technology

All measurements and analysis are based on high-resolution diagnostic images

High confidence in measurements

The Cataract and Refractive Imaging Platform is currently under development and not for sale yet.

Modular Platform

Biometry for IOL calculation Corneal topography/tomography Anterior segment biometry Anterior segment imaging

All in one device

All based on swept-source OCT

The Cataract and Refractive Imaging Platform is currently under development and not for sale yet.

Workflow OptimizationCurrent challenge

Heidelberg Engineering solution

The Cataract and Refractive Imaging Platform is currently under development and not for sale yet.

Image Management and Device Integration

The Cataract and Refractive Imaging Platform is currently under development and not for sale yet.

SPECTRALIS OCT on Board ISS

THANK YOU!

DIAGNOSTICS-IMPACT ON THE PREMIUM CHANNEL: PANEL DISCUSSION

Richard Lindstrom, MD

Moderated By:

Tom FrinziPresident – AMO

SVP – Abbott Laboratories

Participants:

Dave HarmonPresident

Market Scope

Warren Hill, MD

Ludwin Monz, PhDPresident & CEO

Carl Zeiss Meditec AG

Jay Pepose, MD, PhD Vance Thompson, MD

How important are preoperative diagnostics in managing the

premium channel IOL patients?

How large is the market opportunity in preoperative diagnostics.

Are there significant unmet needsin this arena?

Are you seeing significant investment occurring by industry,

including your own company, to meet these unmet needs.

Can one get a good return on investment in diagnostic equipment.

If time: Do you see a need in the future

for companies to pair diagnostics with therapeutics as a package

offering?